Breast Cancer Experts Celebrate the News of KEYNOTE-522

KEYNOTE-522 Delivers Major Advance for TNBC Patients

Researchers discuss the need for biomarkers to tailor treatment options for better quality of life for patients

 

Total Impressions 143,697

KOL Sentiment

 -100100Positive

Sentiment Analysis

Doctor Name Sentiment Comment
Naoto T Ueno, MD, PhD
POSITIVE
Fantastic. But I still believe there is a fraction of people who do not benefit immunotherapy. We need a biomarker driven approach. #ASCO24 #Oncoalert https://t.co/aqpwcmbxC4
Toni Choueiri, MD
POSITIVE
OS with IO on the perioperative setting in breast cancer —big news ! @stolaney1 @OncoAlert @DFCI_BreastOnc https://t.co/43xGV29fvV
Evandro de Azambuja, MD, PhD
POSITIVE
Important Overall Survival results in KEYNOTE-522. Important advance for our patients with #early TNBC, but we are still waiting biomarker analyses for this trial... @FDAOncology @OncoAlert @Merck #bcsm #research https://t.co/bqIp15jGg7
Jame Abraham, MD, FACP
POSITIVE
Overall survival improvement with Immunotherapy in neoadjuvant- triple negative breast cancer ! KEYNOTE 522 https://t.co/WceiHaHD7d
Erika Hamilton, MD
POSITIVE
This is really important and so encouraging to see. Especially in #HER-2 and #TNBC, it's clear DDFS is a surrogate for OS. Now we have to figure if we can give immunotherapy with less chemo than KN522. This can be a tough regimen for many. #bcsm https://t.co/GOjfQVplF8
Sara Tolaney
POSITIVE
very important news! Overall Survival seen in KN522!!! https://t.co/YmwsCohjno
Noelle Girard
POSITIVE
@ErikaHamilton9 Excellent results from KEYNOTE-522! Critical to now review the full data to potentially reduce chemo burden in treatment plans. #BreastCancer #TNBC
Elad Sharon
POSITIVE
Overall survival advantage for the use of pembrolizumab in breast cancer from the Keynote-522 trial. Exciting to see this key secondary endpoint reported! https://t.co/2loDIZeIS9
Elisa Agostinetto
POSITIVE
Today’s press release by Merck: KEYNOTE-522 met its overall survival endpoint in high-risk early TNBC Excellent news for our #breastcancer patients @OncoAlert https://t.co/S1SK9yeggW
Toni Choueiri, MD
POSITIVE
KEYNOTE-522 shows that the addition of neoadjuvant + adjuvant #pembro to neoadjuvant chemo leads to a significant and meaningful improvement in OS [HR, 0.66 (0.95% CI, 0.50-0.87); P=0.0015] in pts w/ high-risk early-stage #TNBC! @myESMO #ESMO24 @OncoAlert https://t.co/MXZ9ASedfA
HopeSRugo
Dr. Hope Rugo
POSITIVE
Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert https://t.co/DA02akjF0H
Dr Amol Akhade
POSITIVE
Excellent discussion 👏. Breast oncologist do it way way better than GU oncologist. 👍🙂 @drsarahsam @stolaney1 @ErikaHamilton9 @hoperugo @myESMO #ESM024 https://t.co/cLX9XwLyXy
Timothée Olivier, MD
POSITIVE
Great and balanced discussion by @lab_kok after the presentation of the KEYNOTE-522 overall survival results (peri-op pembro in early-TNBC) Many unanswered questions and important caveats were brought to attention. Refreshing!#ESMO2024 #ESMO24 https://t.co/ZxrlCYTNrQ
Dr Amol Akhade
NEUTRAL
Keynote 522 . Pembrolizumab in early stage TNBC shows OS benifit. We will love to see the OS data in with those with PCR and those who did not achieve PCR and Based Upon RCB . Remember the EFS benifit was maximum in RCB -2 and RCB -3 had infact detrimental EFS . @stolaney1… https://t.co/9VVkMwH95R https://t.co/394vj3UpKH
Jacob Plieth
NEUTRAL
Quite a turnaround since FDA initially greeted $MRK Keynote-522 filing (on pCR) with a CRL. Benefit likely driven by PD-L1+ves, but that's academic as Keytruda now has an all-comers label in this TNBC setting. https://t.co/BJV2but6T2
Matteo Lambertini, MD PhD
NEUTRAL
Fully agree with super @lab_kok: more @myESMO annual congresses in #Barcelona !!! #ESMO24 #ESMOAmbassadors @OncoAlert @RebeccaDSing https://t.co/GcaHAg8l9V
HopeSRugo
Dr. Hope Rugo
NEUTRAL
Post KN522 critical to study who needs or does not need IO, optimal duration, and chemo options. Studies ongoing! @OncoAlert #ESMO24 @stolaney1 and many more.
Abeid Athman (Omar).
NEUTRAL
Marleen Kok with very thoughtful discussion on the design of the KN522, : do all patients need adjuvant pembrolizumab; the irAEA especially in young women who would like to get pregnant. #ESMO2024 @OncoAlert @myESMO @kevinpunie @matteolambe @PTarantinoMD https://t.co/bnHrPtY4RL https://t.co/hen6ZNlTbF

The KEYNOTE-522 trial has been a focal point of discussion in the oncology community, with significant results presented at the recent #ESMO24 conference. This Phase III trial, presented by Prof. Peter Schmid from @QMBCI, has demonstrated impressive outcomes in the treatment of high-risk early-stage triple-negative breast cancer (TNBC).

 

KEYNOTE-522 Study Design

The KEYNOTE-522 trial encompassed patients with high-risk early-stage TNBC, specifically those with tumors of at least 2 cm or positive lymph nodes, suggesting the introduction of high-risk parameters. The study's structure included:

  1. Neoadjuvant Phase: Patients received neoadjuvant (pre-surgery) treatment with pembrolizumab (an anti-PD-1 therapy) combined with chemotherapy.
  2. Adjuvant Phase: Following surgery, patients continued with pembrolizumab if they had received it preoperatively, or a placebo if they had not.

 

Key Results: Significant Overall Survival (OS) Benefit

The findings from the trial indicated several critical improvements:

  • 5-Year Overall Survival (OS): The rate was 86.6% in the pembrolizumab arm versus 81.7% in the placebo arm, with a Hazard Ratio (HR) of 0.66, denoting a 34% reduction in the risk of death.
  • Event-Free Survival (EFS): The study demonstrated a 9% improvement in EFS over five years.

 

KEYNOTE-522 Discussion Points

The impressive results from the KEYNOTE-522 trial have sparked numerous discussions within the oncology community, with several key points highlighted:

  1. Biomarker Identification: Researchers are keen to identify biomarkers that can predict who will benefit from pembrolizumab. This will help avoid unnecessary treatment and associated toxicities in patients unlikely to respond (Sushil (@Sushilberiwal)

  2. Minimizing Toxicity: The rigorous regimen's toxicity has been a concern, so there's a concerted effort to refine treatment plans to balance efficacy and quality of life (Hope Rugo (@hoperugo), Naoto T Ueno (@teamoncology)).

  3. Tailoring Treatment: There's a significant interest in tailoring the treatment regimen to individual patients, potentially reducing the chemotherapy burden where feasible. This is especially relevant given the different responses observed in patients achieving complete pathologic response (pCR) versus non-pCR (Timothée Olivier, MD (@Timothee_MD)).

  4. Clinical Practice Integration: Researchers and oncologists are exploring how to best integrate these findings into clinical practice, with emphasis on adjusting current treatment protocols based on these results (Sara Tolaney (@stolaney1), Erika Hamilton, MD (@ErikaHamilton9)).